158446-64-1

Upstream product

• 196930-46-8 (4R)-2-phenyl-1,3-thiazolidine-4-carboxylic acid 
• 108-24-7 acetic anhydride 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 874008-12-5 3-Hexin-1,6-dicarbonsaeure-dimethylester 

Downstream Products

• 711016-38-5 5-methyl-2,2-dioxo-3-phenyl-2,3-dihydro-1H-2λ⁶-pyrrolo[1,2-c]thiazole-6,7-dicarboxylic acid dimethyl ester 
• 1252613-16-3 (3R)-6,7-bis (hydroxymethyl)-5-methyl-3-phenyl-1H,3H-pyrrolo [1,2-c]thiazole 

Relevant academic research and scientific papers

Intermolecular dipolar cycloaddition reactions of 5H,7H-thiazolo[3,4- c]oxazol-4-ium-1-olates

(5R)-3-Methyl-5-phenyl-5H, 7H-thiazolo[3,4-c]oxazol-4-ium-1-olate was generated in the presence of a range of dipolarophiles. The intermolecular 1,3-dipolar cycloaddition of this mesoionic species led to the synthesis of chiral 1H-pyrrolo[1,2-c]thiazole derivatives 7a, 7b, 8, 14, 18, 19 and 20. In the reaction with methyl and ethyl vinyl ketone, spiro compounds 9 and 15 were also obtained. The structure of compound 15 was determined by X-ray crystallography. (C) 2000 Elsevier Science Ltd.

"(3S)- AND (3R)-6,7-BIS(HYDROXYMETHYL)-1H,3H-PYRROLO[1,2-C]THIAZOLES AS P53 ACTIVATORS"

The present application relates to compounds of formula I, which are (3S)- and (3R)-6,7-bis(Hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles. The present application also relates to pharmaceutical compositions comprising said compounds and the use of these co

Chiral 6-hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: Novel antitumor DNA monoalkylating agents

New chiral 1H,3H-pyrrolo[1,2-c]thiazoles were synthesized and screened for their in vitro activity as anti-cancer agents in three human tumor cell lines, colorectal adenocarcinoma, melanoma and breast adenocarcinoma. (R)-6-Hydroxymethyl-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole and the corresponding benzylcarbamate showed selectivity for breast cancer cell lines with IC50 values of 2.4 μM and 2.2 μM, respectively. The latter also showed significant activity against colorectal adenocarcinoma cancer cell lines (IC50 = 8.7 μM). In contrast, the 7-hydroxymethyl-5-methyl- 3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole gave moderate anti-cancer activity. The performance against breast cancer cell lines (IC50 = 1.0 μM) of a potential bisalkylating agent, a (3R)-6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2- c]thiazole, wasn't significantly different from the one observed for the monoalkylating derivatives indicating that the main mechanism of action may in fact be the monoalkylation process.